{"nctId":"NCT00421148","briefTitle":"Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)","startDateStruct":{"date":"2005-05-30","type":"ACTUAL"},"conditions":["Anesthesia"],"count":94,"armGroups":[{"label":"Sugammadex 0.5 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Sugammadex 0.5 mg/kg","Drug: Rocuronium bromide"]},{"label":"Sugammadex 1 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Sugammadex 1 mg/kg","Drug: Rocuronium bromide"]},{"label":"Sugammadex 2 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Sugammadex 2 mg/kg","Drug: Rocuronium bromide"]},{"label":"Sugammadex 4 mg/kg","type":"EXPERIMENTAL","interventionNames":["Drug: Sugammadex 4 mg/kg","Drug: Rocuronium bromide"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Rocuronium bromide"]}],"interventions":[{"name":"Sugammadex 0.5 mg/kg","otherNames":["Org 25969","MK-8616","SCH 900616"]},{"name":"Sugammadex 1 mg/kg","otherNames":["Org 25969","MK-8616","SCH 900616"]},{"name":"Sugammadex 2 mg/kg","otherNames":["Org 25969","MK-8616","SCH 900616"]},{"name":"Sugammadex 4 mg/kg","otherNames":["Org 25969","MK-8616","SCH 900616"]},{"name":"Placebo","otherNames":["sodium chloride 0.9% solution"]},{"name":"Rocuronium bromide","otherNames":["ESMERON®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) class 1 - 2, between the ages of 28 days and 65 years inclusive, and between the ages of 2 and 65 years inclusive for Germany and between the ages of 6 and 65 years inclusive for Finland\n* Scheduled for general anesthesia with an anticipated duration of anesthesia of at least 60 minutes, without further need for muscle relaxation other than one single dose of 0.6 mg/kg rocuronium\n* Scheduled for surgical procedures in the supine position\n* Participants who, and/or whose parent(s) or legal guardian(s) have given written informed consent \\[or appropriate assent, if applicable\\]\n\nExclusion Criteria:\n\n* Known or suspected neuromuscular disorders impairing neuromuscular blockade (NMB) and/or significant renal dysfunction, in Germany creatinine and blood urea nitrogen outside local reference ranges\n* Known or suspected to have a (family) history of malignant hyperthermia\n* Known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia\n* Use of medication expected to interfere with the rocuronium given in this trial, based on the dose and the time of administration\n* Pregnancy\n* Childbearing potential not using any of the following methods of birth control: condom or diaphragm with spermicide, vasectomized partner (\\>6 months), intrauterine device (IUD), abstinence\n* Breast-feeding\n* Prior participation in any study with Org 25969 (sugammadex)\n* Participation in another clinical trial, not pre-approved by NV Organon, within 30 days of entering into study 19.4.306 (MK-8616-034, P05961)","healthyVolunteers":false,"sex":"ALL","minimumAge":"28 Days","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.9","description":"Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds \\& assessing twitch response at the adductor pollicis muscle. T1 \\& T4 refer to the magnitudes (heights) of the first \\& fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached ≥0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.98","spread":"11.30"},{"groupId":"OG001","value":"3.72","spread":"0.63"},{"groupId":"OG002","value":"2.42","spread":"0.70"},{"groupId":"OG003","value":"0.58","spread":"NA"},{"groupId":"OG004","value":"19.57","spread":"10.97"},{"groupId":"OG005","value":"5.22","spread":"3.50"},{"groupId":"OG006","value":"3.95","spread":"3.23"},{"groupId":"OG007","value":"1.20","spread":"0.35"},{"groupId":"OG008","value":"1.57","spread":"1.90"},{"groupId":"OG009","value":"22.77","spread":"13.10"},{"groupId":"OG010","value":"11.97","spread":"17.65"},{"groupId":"OG011","value":"1.77","spread":"0.37"},{"groupId":"OG012","value":"1.87","spread":"1.70"},{"groupId":"OG013","value":"1.08","spread":"0.25"},{"groupId":"OG014","value":"29.48","spread":"8.43"},{"groupId":"OG015","value":"3.77","spread":"1.12"},{"groupId":"OG016","value":"1.62","spread":"0.30"},{"groupId":"OG017","value":"1.27","spread":"0.27"},{"groupId":"OG018","value":"1.37","spread":"0.38"},{"groupId":"OG019","value":"0.67","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.7","description":"Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds \\& assessing twitch response at the adductor pollicis muscle. T1 \\& T4 refer to the magnitudes (heights) of the first \\& fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.85","spread":"8.65"},{"groupId":"OG001","value":"2.47","spread":"0.07"},{"groupId":"OG002","value":"1.78","spread":"0.18"},{"groupId":"OG003","value":"0.58","spread":"NA"},{"groupId":"OG004","value":"12.32","spread":"7.00"},{"groupId":"OG005","value":"2.62","spread":"0.93"},{"groupId":"OG006","value":"1.45","spread":"0.38"},{"groupId":"OG007","value":"0.75","spread":"0.12"},{"groupId":"OG008","value":"0.57","spread":"0.13"},{"groupId":"OG009","value":"18.62","spread":"9.72"},{"groupId":"OG010","value":"2.77","spread":"1.27"},{"groupId":"OG011","value":"1.07","spread":"0.12"},{"groupId":"OG012","value":"0.95","spread":"0.30"},{"groupId":"OG013","value":"0.83","spread":"0.20"},{"groupId":"OG014","value":"19.65","spread":"5.38"},{"groupId":"OG015","value":"1.62","spread":"0.25"},{"groupId":"OG016","value":"1.27","spread":"0.35"},{"groupId":"OG017","value":"0.87","spread":"0.23"},{"groupId":"OG018","value":"1.12","spread":"0.38"},{"groupId":"OG019","value":"0.42","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Time From Start of Administration of Study Treatment (Sugammadex or Placebo) to Recovery T4/T1 Ratio to 0.8","description":"Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds \\& assessing twitch response at the adductor pollicis muscle. T1 \\& T4 refer to the magnitudes (heights) of the first \\& fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.85","spread":"10.42"},{"groupId":"OG001","value":"2.97","spread":"0.07"},{"groupId":"OG002","value":"2.03","spread":"0.17"},{"groupId":"OG003","value":"0.58","spread":"NA"},{"groupId":"OG004","value":"14.20","spread":"8.32"},{"groupId":"OG005","value":"3.42","spread":"1.40"},{"groupId":"OG006","value":"1.85","spread":"0.70"},{"groupId":"OG007","value":"0.95","spread":"0.23"},{"groupId":"OG008","value":"0.75","spread":"0.45"},{"groupId":"OG009","value":"21.92","spread":"12.52"},{"groupId":"OG010","value":"4.92","spread":"4.08"},{"groupId":"OG011","value":"1.35","spread":"0.17"},{"groupId":"OG012","value":"0.98","spread":"0.38"},{"groupId":"OG013","value":"0.87","spread":"0.18"},{"groupId":"OG014","value":"24.77","spread":"9.33"},{"groupId":"OG015","value":"2.22","spread":"0.60"},{"groupId":"OG016","value":"1.37","spread":"0.35"},{"groupId":"OG017","value":"1.07","spread":"0.23"},{"groupId":"OG018","value":"1.27","spread":"0.30"},{"groupId":"OG019","value":"0.67","spread":"NA"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":["Procedural pain","Vomiting","Nausea","Constipation","Pain"]}}}